Abstract：
Pregnancy during or soon after treatment with weight loss medication, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), is contraindicated due to potential teratogenicity. The aim of this scoping review is to investigate what is known about the use of weight loss medication in women of childbearing age in relation to reproductive health outcomes, focusing on the three medications licenced in the United Kingdom at the time of the search. A systematic search of studies that assessed reproductive health outcomes in women taking either orlistat, liraglutide or semaglutide was undertaken in July 2023 and updated in January 2024 across MEDLINE, Embase, CINAHL, Scopus, ClinicalTrials.gov, PROSPERO, Epistemonikos and OpenGrey. Studies focused on polycystic ovarian syndrome, diabetes or animals were excluded. Titles and abstracts were screened, and data from included articles were extracted. After removal of duplicates, 341 titles remained, of which 318 were excluded. Of the final 18 articles included, there were five interventional trials, one retrospective case-control study, six narrative reviews, two systematic reviews, three systematic review protocols and one registry protocol yet to start recruitment. All five interventional trials involved orlistat given preconceptionally, showing no improvement in live birth rate, despite improvement in reproductive hormone levels. There were no studies with primary data about GLP-1 RAs. There were no qualitative studies. There is an absence of primary data about the role of GLP-1 RAs on the reproductive health of women of childbearing age without polycystic ovarian syndrome. Future research should explore short- and long-term effects on reproductive health, pregnancy outcomes and experiences.
摘要：
在使用减肥药物治疗期间或之后不久怀孕，特别是胰高血糖素样肽-1受体激动剂（GLP-1RA），由于潜在的致畸性而禁忌。这项范围审查的目的是调查育龄妇女使用减肥药物与生殖健康结果有关的已知情况，重点关注搜索时在英国获得许可的三种药物。对评估服用奥利司他的女性生殖健康结果的研究进行了系统的搜索，利拉鲁肽或司马鲁肽于2023年7月进行，并于2024年1月在MEDLINE进行了更新，Embase,CINAHL,Scopus,ClinicalTrials.gov,PROSPERO,Epistemonikos和OpenGrey。研究集中在多囊卵巢综合征，排除糖尿病或动物。标题和摘要进行了筛选，并从纳入的文章中提取数据。删除重复项后，仍有341个头衔，其中318人被排除在外。在包括的最后18篇文章中，有五项介入试验，一项回顾性病例对照研究，六个叙事评论，两次系统审查，三项系统审查协议和一项登记册协议尚未开始征聘。所有五项介入试验都涉及奥利司他，活产率没有改善，尽管生殖激素水平有所改善。没有关于GLP-1RA的主要数据的研究。没有定性研究。缺乏关于GLP-1RA对没有多囊卵巢综合征的育龄妇女的生殖健康的作用的主要数据。未来的研究应该探索对生殖健康的短期和长期影响，妊娠结局和经验。
